Horizon Therapeutics Receives $7,294,000 New Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ea6e458f-e4e3-4604-81c6-a17296122279&Preview=1 -
Date
3/31/2010 -
Company Name
Horizon Therapeutics -
Mailing Address
1033 Skokie Boulevard Northbrook, IL 60062 -
Company Description
Horizon Therapeutics, Inc. is a late stage biopharmaceutical company focused on the rapid development and commercialization of therapeutic treatments for mild-to-moderate pain management. The Company is building a novel portfolio of therapies through innovative combinations of approved pharmaceutical products that seek to improve safety, efficacy, and patient compliance. Its lead product candidate, HZT-501, will enter Phase 3 trials in 2007. In addition to HZT-501, Horizon has a pipeline of follow-on pain combination products in earlier stages of development. -
Website
http://www.horizontherapeutics.com -
Transaction Type
Venture Equity -
Transaction Amount
$7,294,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
Proceeds purposes were not disclosed. -
M&A Terms
-
Venture Investor
Essex Woodlands Health Ventures -
Venture Investor
Undisclosed
